Abstract
Objective To investigate the changes of plasma resistin and lysophosphatidic acid and their roles in cerebral infarction. Methods Enzyme-linked immunosorbent assay (ELISA) was used to measure the plasma resistin levels in 130 patients with cerebral infarction, 40 with other neurological diseases (20 with sciatica and 20 with trigeminal neuralgia), and 60 healthy control subjects. Lysophosphatidic acid was isolated from the blood samples from the subjects and quantified by assaying its phosphorous component. Results The plasma levels of resistin and lysophosphatidic acid were significantly higher in patients with cerebral infarction than those in the other two groups (P<0.05). In patients with cerebral infarction, higher plasma resistin and plasma lysophosphatidic acid levels were associated with increased infarct size, and their levels were also found to closely correlate to the neurological deficits in the patients. Conclusion Detection of the plasma levels of resistin and lysophosphatidic acid may help estimate the severity of cerebral infarction, the infarct size and the degree of neurological deficits. Key words: Resistin; Plasma lysophosphatidic acid; Cerebral infarction
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
